MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
870.00
-24.00 (-2.68%)
At close: Apr 28, 2026
Market Cap36.69B -25.0%
Revenue (ttm)11.22B -28.2%
Net Income-13.05B
EPS-340.00
Shares Out42.17M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume108,729
Average Volume444,680
Open897.00
Previous Close894.00
Day's Range870.00 - 910.00
52-Week Range577.00 - 2,250.00
Beta0.67
RSI41.25
Earnings DateMay 15, 2026

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

In 2025, MOA Life Plus's revenue was 11.22 billion, a decrease of -28.24% compared to the previous year's 15.63 billion. Losses were -13.05 billion, 88.6% more than in 2024.

Financial Statements